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Abstract 
Purpose:  Recently approved immunotherapies capitalize on antitumor mechanisms of the 
patient’s immune system by inhibiting CTLA-4 and PD-1 pathways. Studies have shown better 
overall survival with increased tumor infiltrating lymphocyte (TIL) across multiple cancers.  
Recent trials with anti-PDL-1 has shown better response with high PDL-1 expression.  However, 
studies have not evaluated whether TIL level would correlate with anti-PDL-1 or anti-CTLA-4 
responses.  The aim of this study is to determine if the level of TIL in metastatic melanoma and 
lung cancer correlates with patient response to modern immunotherapies.  
Methods: We identified 10 patients with melanoma or lung cancer treated with an immune 
checkpoint inhibitor. The biopsy samples were stratified according to level of TIL. The TIL 
categories ranged from 0 to 3, with 0 indicating no TIL detected and 3 indicating 67-100% TIL 
infiltration. Survival analysis was achieved with Kaplan-Meier curve, and tumor size change was 
evaluated with linear mixed model analysis.  
Results: Overall survival was significantly longer in patients who had TIL (TIL=1-3 vs. TIL=0, 
p=0.024). For TIL 0, there was average decrease in size from baseline to first follow up of 
0.12cm2. Tumor size also dramatically decreased based on TIL level (TIL 1-2: 371% greater 
decrease than TIL 0, p < 0.01; TIL 3: 406%; p<0.01). The overall survival from time of initial 
treatment was 0.3 yr for TIL 0 (SD=0.2), 2.45 yr for TIL1-2 (SD=0.71), and 1.56 yr for TIL 3 
(SD=1.27). After controlling for baseline tumor size and the type of cancer, the mean difference 
in the change of tumor size between baseline and the following time point was 0.74cm2 smaller 
in TIL 1-2 compared to TIL=0 (p=0.002). Furthermore, the estimated mean difference in the 
change in tumor size between baseline and the following time point was 0.74cm2 lower in 
patients with TIL=3 compared to TIL=0 (p=0.002) 
Conclusion: Our study shows that TIL level may serve as a biomarker of tumor response to 
immunotherapy, without specific histochemical staining. This study is limited by the low 
number; a larger review is currently taking place. 
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Introduction 
The treatment of cancer has largely relied upon the killing of tumor cells through 
cytotoxic chemotherapies and radiation. However, these therapies have their limitations: 
cancer cells can develop resistance to these drugs, and radiation therapy is a localized, not 
systemic, treatment. Additionally, there is large profile of side effects associated with these 
therapies. These reasons warrant a closer look at other approaches to cancer therapy, 
specifically the immune mechanisms modulating cancers.  
Cancer Immunology 
The cancer immunoediting view is now the prevailing theory regarding the 
immunobiology of cancer. This process emphasizes both the host-protective and tumor-
evolving qualities of the immune system in tumor development. It consists of three phases: 
elimination, equilibrium, and escape1. The elimination phase, or cancer immunosurveillance, is 
the process in which molecules and cells of the immune system detect the presence of a tumor. 
These include lymphocytes such as cytotoxic T lymphocytes (CD8+), regulatory T cells (CD4+), B 
cells, natural killer (NK) cells, and other antigen-presenting cells (APC). They invade and 
eliminate it before it manifests itself clinically. The equilibrium phase occurs when tumor cells 
are not completely eliminated, but the immune system controls excessive growth. This results 
in tumor dormancy. Finally, in the escape phase, transformed cells acquire mechanisms that 
allow them to grow and evade the immune system. It is this phase that is of particular interest 
in developing cancer therapies.  
Immune checkpoints  
While traditional cancer therapies are toxic chemicals that destroy tumor cells, great 
interest has been growing in stimulating the patient’s own immune response to fight cancer. 
Notably, melanoma and more recently, lung cancer, are considered to be immunogenic 
cancers, and thus are responsive to immunologic modulation2. One obstacle in the immune 
response is immune checkpoints. These are inhibitory proteins that regulate the immune 
system, and prevent an active immune response to certain stimuli. Immune checkpoints 
proteins do this by binding to a specific ligand. This is an important homeostatic mechanism in 
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preventing tissue injury and autoimmunity, however cancer cells can capitalize on this 
mechanism to evade immune destruction. Two specific immune checkpoint proteins that are 
expressed on T-lymphocytes have become of interest in recent cancer immunotherapy 
research: programmed cell death-1 (PD-1) and cytotoxic T-lymphocyte antigen 4 (CTLA4). When 
interacting with their ligands, PD-L1 and B7 respectively, these checkpoint proteins inhibit an 
active T-cell response3. For example, the signaling of PD-1 prevents T-cell activation, and leads 
to reduced proliferation, cytokine production, and T-cell cytolysis4. It has been found that 
tumor cells express PD-L1 following infiltration of T-lymphocytes5, leading to the hypothesis 
that blocking the PD-1/PD-L1 pathway can lead to an active immune response against cancer 
cells6. Rodent studies of PD-L1 blockade and PD-1 knockout mice show increased immune 
response7,8. This led to the development of immune checkpoint inhibitors as a novel cancer 
therapy, with the first anti-CTLA4 antibody, ipilimumab, being FDA approved in 20119. 
Pembrolizumab and nivolumab are two other monoclonal antibodies, specifically targeting PD-
1. These immune checkpoint inhibitors thwart the interaction between tumor cells and T-
lymphocytes to release immune inhibition, and thus promote an antitumor immune response 
against the cancer cells. Recent clinical trials on immune checkpoint inhibitors (ipilimumab, 
pembrolizumab, nivolumab) have yielded incredible success in patients with melanoma and 
lung cancer where durable remission and responses have been achieved, along with a lower 
profile of side effects2,8,10,11. Immune checkpoint inhibitors have become the standard of care 
for many cancer types, but there is still a high variability in patient response rates with 
emerging resistance to these therapies12. This necessitates the identification of biomarkers that 
can inform the use of these agents in patients.  
Immune checkpoint inhibitors and tumor-infiltrating lymphocytes 
Although tumors with high PD-L1 expression have shown an enhanced response to 
immune checkpoint inhibitors, even tumors without PD-L1 expression can respond to these 
therapies. This raises question as to whether other pathways are also influenced by these 
drugs. Recently, research efforts on immune checkpoint inhibitors are focusing on the 
investigation of predictive biomarkers that would aid in patient selection and response 
prediction. 
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Studies have shown that PD-L1 expression was correlated with overall survival, but was 
not independent, suggesting T-cell content as a confounding variable8. Thus, the lymphocytic 
density in the tumor may be a factor. In fact, the level of PD-L1 has been highly correlated with 
the level of tumor infiltrating lymphocytes (TIL), both with uni- and multivariable analysis9. This 
supports an adaptive resistance mechanism for immune escape13. Given the high correlation 
between PD-L1 and TIL, this lends to the hypothesis that patients with a high TIL level would 
have improved response to immune checkpoint therapies. Researchers have identified TIL as an 
important prognostic factor in melanomas and other tumors14,15. Additionally, median survival 
period was significantly correlated with immune cell infiltrate, specifically CD8+ T cells, in 
metastatic tumors of melanoma15. Furthermore, CD8+ T-lymphocytes correlated with response 
of melanoma to pembrolizumab in metastatic melanoma patients3. Thus, this study aims to 
further explore the possibility that tumor response to these therapies is correlated to TIL level 
in tumor samples. This study will be a retrospective review of adult patients who were 
diagnosed with metastatic melanoma or lung cancer, and were subsequently treated with an 
immune checkpoint inhibitor. Biopsies of the metastases will be assessed histologically for TIL 
concentration. Levels of TIL will be correlated with patient response. We hypothesize that the 
level of TIL in metastases of melanoma or lung cancer in adult patients who received immune 
checkpoint inhibitor treatment will positively correlate with overall survival. 
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Materials and Methods 
Chart Review 
Analysis of specimens and collection of data was approved by the Banner Institutional 
Review Board. Patients were treated at some point between 2012 and 2015. Subjects were 
identified through a report generated from the Cerner electronic medical record system. 
Inclusion criteria included patients between ages 18-99 years who were diagnosed with 
metastatic melanoma or lung cancer treated with an immune checkpoint inhibitor at our 
institution between January 1, 2012 and December 31, 2015. Immune checkpoint inhibitors 
included ipilimumab, pembrolizumab, or nivolumab. Exclusion criteria included patients who 
were not treated with immune checkpoint inhibitors, or patients who were not evaluated at 
our institution. These criteria yielded a total of 104 subjects. 
Information retrieved from patient records included diagnosis, treatment, response to 
treatment, timeline of treatment, follow-up reports, pathology reports, and radiology reports. 
Determination of TIL expression 
One pathologist examined the biopsies of subjects and selected a representative slide of 
the collected specimens. The cohort included a total of 10 patients. The biopsies were collected 
from either primary or metastatic lesions, and stained with hematoxylin and eosin. The level of 
TIL was analyzed microscopically and quantified according to a 4-tiered system, correlating with 
the percentage of lymphocytic infiltrate by area of the biopsy specimen (Table 1). TIL level of 0 
represented 0% TIL, TIL level of 1 represented a TIL area of 1-33%, TIL level of 2 represented a 
TIL area of 34-67%, and TIL level of 3 represented a TIL area of 68-100%. All histologic analysis 
and categorization was completed by the same pathologist.  
Statistical Analysis 
One of the primary endpoints for analysis was the overall survival and its association 
with TIL level. Overall survival was analyzed using the Kaplan-Meier method. Patients were 
stratified according to variations of the TIL level and survival curves were constructed. A linear 
mixed model analysis was used to test the association between TIL level and tumor size over 
time.  
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TIL level Level of lymphocytic infiltrate in biopsy sample 
0 0% (no lymphocytes) 
1 1-33% 
2 34-67% 
3 68-100% 
Table 1. The level of TIL was quantified according to a 4-tiered system, correlating with the 
percentage of lymphocytic infiltrate by area of the biopsy specimen 
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Results 
Patient Demographics 
The study included a total of ten patients, comprised of four males and six females with 
mean age of 62.8 years (Range: 48-88) at time of the start of treatment. Of these patients, six 
were diagnosed with melanoma, and four were diagnosed with lung cancer.  Eight patients 
were deceased at time of analysis, and two were alive. Overall survival (OS) was defined as time 
of treatment start to time of death or time of last clinical encounter. The average OS was 16.4 
months, with a range of 1-39 months. Four patients had a TIL level of 0, two patients had a TIL 
level of 1, one patient had a TIL level of 2, and three patients had a TIL level of 3. Other patient 
characteristics are outlined in Table 2. 
Overall survival and TIL level 
One of the primary analyses of this study was to analyze the level of TIL and its 
relationship with overall survival. Kaplan-Meier analysis was performed, measuring overall 
survival from treatment start date to death (or last encounter) and TIL. The first analysis 
categorized patients with and without any lymphocytic infiltrate in the biopsy sample. Patients 
with TIL exhibited a significantly longer OS than patients with TIL 0 (TIL 1-3 vs. TIL 0, p=0.024), 
with no TIL 0 patients alive after 6 months (Figure 1). A further comparison of TIL level 0 with 
TIL levels 1-2 and 3 revealed a significantly longer OS for patients with TIL 1-2 and TIL 3 
compared with TIL 0 (TIL 0 vs. TIL 1-2 vs. TIL 3, p=0.04) (Figure 2). The overall survival from time 
of initial treatment was 0.3 yr for TIL 0 (SD=0.2), 2.45 yr for TIL1-2 (SD=0.71), and 1.56 yr for TIL 
3 (SD=1.27). 
Tumor size and TIL level 
For TIL 0, there was average decrease in size from baseline to first follow up of 0.12cm2. 
A linear mixed model was used to evaluate change in tumor size across TIL levels. Patients with 
TIL 1-2 level showed a 371% decrease in size compared to TIL 0 (p < 0.01), while TIL level 3 
showed a 406% decrease in size compared to TIL 0 (p < 0.01). After controlling for baseline 
tumor size and the type of cancer, the mean difference in the change of tumor size between 
baseline and the following time point was 0.74 cm2 smaller in TIL 1-2 compared to TIL 0 
7 
 
(p=0.002). Furthermore, the estimated mean difference in the change in tumor size between 
baseline and the following time point was 0.74 cm2 lower in patients with TIL 3 compared to TIL 
0 (p=0.002).  
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Patient Sex Cancer type Age at tx start 
TIL 
level Location of mass 
OS  
(in days) 
A M Melanoma 50 1 Brain  1015 
B M Melanoma 54 3 Femur 895 
C M Melanoma 48 3 Nose 777 
D F Melanoma 70 0 Liver 179 
E F Melanoma 54 1 Parietal scalp 594 
F M Melanoma 88 2 Temporal scalp 1175 
G F Lung Cancer 63 0 Mainstem bronchus 168 
H F Lung Cancer 73 0 Lung 50 
I F Lung Cancer 57 0 Vertebral body 41 
J F Lung Cancer 71 3 Lung 35 
Table 2. Characteristics of patients included in this study 
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Figure 1. Kaplan-Meier curve for probability for survival by TIL 0 vs 1-3.  Time=0 is the treatment 
start date.  
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Figure 1. Kaplan-Meier curve for probability for survival by TIL 0 vs 1-2 vs 3.  Time=0 is the 
treatment start date.  
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Discussion 
While immune checkpoint therapies have been shown to be more effective than other 
therapies, there are still many patients that do not respond to treatment and continue to 
progress. Studies have established a greater response to immune checkpoint therapy in more 
immunogenic tumors. Tissue samples with a greater presence of immune checkpoint proteins 
correlate with longer survival compared to those that lack them. It is crucial to have a reliable 
biomarker that allows physicians to predict response to immune checkpoint blockades, and 
thus tailor treatments to the characteristics of the tumor.   
Our study supports those of others in identifying TIL density as a predictor for immune 
checkpoint inhibitor response. We studied 10 patients who were treated with a form of 
immune checkpoint inhibitor for either metastatic melanoma or lung cancer. We confirmed the 
association between higher TIL levels and increased overall survival. In fact, when comparing 
patients with and without any TIL, there was a stark difference in overall survival. Comparing 
tier-based levels of TIL further supported the association, with patients with higher TIL levels 
having a longer OS. While this study included a low number of subjects, it can be concluded 
with statistical significance that a higher level of TIL was associated with a longer overall 
survival compared to groups with lower TIL levels in patients on immune checkpoint inhibitors. 
This ultimately lends to the concept of utilizing TIL level as a predictive biomarker to guide 
patient treatment. With precision oncology on the rise, the incorporation of predictive markers 
for response to immunotherapy is critical to identify which patients are most likely to benefit. 
Efforts have focused on profiling of the immune microenvironment and predictive immune-
associated biomarkers. Thus far, PD-L1 expression has been the most studied biomarker thus 
far. It is the only biomarker of its type to have FDA approval for its immunohistochemistry 
staining as a companion diagnostic16.  
There are other immuno-oncologic biomarkers that have been studied; however, their 
clinical utility and availability is limited. These include mutation load, neoantigens, and ratio of 
CD8+ T cells to FoxP3+ regulatory T cells16. Other predictors of patient response to 
immunotherapy include age, smoking status, tumor histology, and treatment history17. It is 
12 
 
important to note that there are some obstacles in using immunologic markers. There is great 
variability in tumor samples within an individual patient, making some biopsy samples less 
reliable for these types of biomarkers18. Additionally, the immune environment of the tumor is 
dynamic in that it can be upregulated in general inflammatory processes and can change as 
treatment progresses. More research is needed to develop a companion diagnostic for these 
translational biomarkers, like that of PD-L1.  
Perhaps the most dramatic outcomes of our study lie in the radiologic data, showing a 
greater decrease in tumor size in patients with higher TIL levels. Patients with any TIL density 
had a greater than 350% decrease in tumor size compared to those patients with no TIL’s 
visualized on biopsy sample. Not only does this support existing evidence for enhanced patient 
response in tumors with high TIL levels, but it provides an objective measure by which to assess 
level of progression. There have not been any published studies utilizing imaging data to assess 
patient response to immunotherapy. A stronger establishment of the relationship between TIL, 
PD-L1, and patient response can ideally lend to the future development of a radiological 
biomarker for PD-L1 and/or TIL. More research is warranted to identify radiologic 
characteristics of responders vs. non-responders. This will allow for less invasive 
characterization of the tumor, as well as a more effective and efficient decision of therapy. 
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Future Directions 
While this study showed strong and statistically significant correlations, it was limited by 
sample size. The inclusion criteria warranted over 100 patients, however many had to be 
excluded due to development of toxicities and adverse events from the immune therapies, and 
thus continued with palliative care. While leaving us with a sample size of 10, this speaks 
volumes to the need for a predictive biomarker to identify patients in whom the risks of the 
immune therapies are outweighed by the potential benefits. A larger sample size would 
undeniably provide a greater body of evidence to the findings in this study. A larger sample size 
for each TIL tier would provide more insight. There were other limitations to the study design, 
such as the limitations in the histologic staining. Because this was a retrospective review, biopsy 
slides could not be stained for specific T-cell markers, such as CD8+ and CD4+. Level of TIL was 
dependent upon the pathologist’s experience in identifying lymphocytic infiltrate on the biopsy 
slides under light microscopy.  
Newer technologies, including multispectral imaging and detection systems, can provide 
greater detail about the specific protein antigens and immune cell types in a single biopsy 
sample12. Future studies should utilize these technologies for better immune cell profiling and 
identification of predictive biomarkers. Furthermore, using this technology would address the 
need for criteria to quantify TIL and establish a threshold for predicted patient response. Future 
research should focus on development of diagnostic companions for research biomarkers as 
well as utilizing imaging for less invasive tumor characterization. 
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Conclusions 
Despite the limitations, our study contributes to the body of evidence and movement 
towards establishing predictive translational biomarkers for immune therapies. We supported 
existing evidence showing increased overall survival in patients receiving immune checkpoint 
inhibitor therapy with higher TIL levels in the biopsied samples. More importantly, we showed 
radiologic data to support this, with greater tumor response in patients with higher TIL levels. 
There is promise in utilizing radiologic parameters for tumor characterization and follow-up.  
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